Popular search terms:
Search Results
16 results found-
CSL Seqirus is a world leader in developing and producing influenza vaccines. Learn more about how we work with our partners to protect the global community.
https://www.cslseqirus.co.nz/products -
Learn more about how we're leveraging cutting-edge technology and proven expertise to develop influenza vaccines and respond to pandemic threats.
https://www.cslseqirus.co.nz/ -
CSL Seqirus is a global influenza vaccine company developing innovative solutions to ensure epidemic and pandemic preparedness throughout the world.
https://www.cslseqirus.co.nz/our-company -
Gary Wu The Doctors, 205 Great South Road, 27.8.2025 Advanced Influenza Vaccines 27.8.2025 $2,160.00 (incl GST) Advisory Board attendance $2,484.00 (incl GST) Greenlane Greenlane, Auckland NZ Advisory Board meeting fee Rita Muller Te Whatu Ora - 16-24 Commerce Street, 27.8.2025 Advanced Influenza Vaccines Travel $320.00 27.8.2025 $640.00 (excl GST) Advisory Board attendance $988.00 (excl GST) Northland/IMAC Whangarei NZ Advisory Board Parking $28.00 fee Allan Moffitt ProCare Health PO Box 105 346, Auckland 27.8.2025 Advanced Influenza Vaccines 27.8.2025 $1575.00 (excl GST) Advisory Board attendance $1,811.25 (incl GST) NZ Advisory Board fee Caerlie Picken, Ranolf Medical Centre 59 Ranolf Street, Victoria, 27.8.25 Advanced Influenza Vaccines Taxi and mileage $130.19 27.8.2025 $1,200 (Excl GST) Advisory Board Fees $1,730.14 (incl GST) Nurse Practitioner Rotorua 3215 NZ Advisory Board (incl GST) Flight $313.69 (incl GST) Travel cost - $400.00 (excl GST) Vicky Chan Unichem Pakuranga 11-13 Cortina Place, 27.8.2025 Advanced Influenza Vaccines 27.8.2025 $1,500.00 (excl GST) Advisory Board attendance $1,725.00 (incl GST) Pharmacy Pakuranga NZ Advisory Board fee Transfers to HCOs Recipient Details Event details Activity details Recipient Total Name of HCO Address Location Date of Event Name Registration Fees Travel & Date of Fees for Details e.g. Total (incl/ ex Event (incl/ ex GST) Accommodation Activity Service and Speakers Fees / GST) Costs (incl/ ex Consultancy Advisory Board GST) (incl/ ex GST) Fees / Consultancy Service etc. IMAC C/o University of Auckland 3-5 Sept 2025 Aotearoa NZ Immunisation 3-5 Sept 2025 Bronze Sponsorship $11,500 (incl GST) Auckland, Private Bag Conference 92019, Victoria Street West, Auckland 1142 Worldwise Travel PO Box 109-123, Auckland July 2025 Worldwise Travel July 2025 Silver Sponsorship $2,5000 (excl GST) Newmarket, Auckland Masterclass Epilepsy New Zealand PO Box 1074, Hamilton 3240 20-21 August National Workshop 20-21 August Sponsorship $2,500 (excl GST) 2025 2025
https://www.cslseqirus.co.nz/-/media/seqirus-new-zealand/documents/tov_2025_master-file.pdf -
We are committed to ensuring early and reliable supply of influenza vaccines using both egg and cell-based manufacturing technologies.
https://www.cslseqirus.co.nz/manufacturing -
CSL Seqirus' corporate responsibility (CR) efforts include ethical business practices and contributing to the well-being of our global communities. Learn more.
https://www.cslseqirus.co.nz/our-company/corporate-responsibility -
® 2 FILSPARI (Sparsentan) Dual ETA & AT1 antagonist (IgAN) NR European Union KORSUVA® KOR Agonist (CKD-aP)3 NR Saudi Arabia TAVNEOS ® Oral C5a Receptor Inhibitor (AAV)4 NR Israel, Korea, Saudi Arabia, Qatar VELTASSA ® Oral Potassium Binder (HK) NI European Union, Great Britain (for treatment of hyperkalaemia in adults and adolescents aged 12-17 yrs) Vaccines Develop products for the prevention of infectious disease CELLDEMIC® Influenza (H5N1 ) vaccine zoonotic monovalent, NR European Union adjuvanted (inactivated, cell-based) FLUAD® QUADRIVALENT Influenza vaccine, adjuvanted NR Argentina (surface antigen, inactivated, egg-based)5 FLUAD® QUADRIVALENT Influenza vaccine, adjuvanted NI European Union (for prevention of influenza in persons aged (surface antigen, inactivated, egg-based)5 50 yrs of age and older) FLUCELVAX® QUADRIVALENT Influenza vaccine NI Australia, Great Britain, New Zealand (for prevention of (surface antigen, inactivated, cell-based)6 influenza in persons aged 6m+) FOCLIVIA® Influenza A (H5N1) pandemic vaccine, adjuvanted (egg-based) NR Argentina (for prevention of influenza in persons aged 6m+) FOCLIVIA® Influenza A (H5N1) pandemic vaccine, adjuvanted (egg-based) NI Great Britain, European Union (for prevention of influenza in persons aged 6m+) INCELLIPAN® Influenza pandemic vaccine monovalent, adjuvanted NR European Union (inactivated, cell-based)7 PANVAX® Influenza (H5N8) pre-pandemic vaccine zoonotic monovalent, NR Australia adjuvanted (egg-based) CSL Vifor Focus and deliver products for the treatment of iron deficiency FERINJECT® (ferric carboxymaltose) NR Canada, Switzerland, Egypt FERINJECT® (ferric carboxymaltose) NI Australia (for treatment of iron deficiency anaemia in children aged 1-13 yrs)
https://www.cslseqirus.co.nz/-/media/shared/documents/annual-report/csl-annual-report-2024.pdf -
Learn more about how we're leveraging cutting-edge technology and proven expertise to develop influenza vaccines and respond to pandemic threats.
https://www.cslseqirus.co.nz/healthcare-professionals -
Adverse Reactions (Clinical Body System Frequency Trials, n=1307) Very common Injection-site reaction, injection-site General disorders and (≥1/10) Induration, Asthenia, fever, fatigue administration-site condition Common Influenza-like (≥1/100 and illness, injection-site erythema <1/10) Rare Chills ≥1/10,000 and <1/1,000 Very common Rash Skin and subcutaneous (≥1/10) disorders Common Urticaria (≥1/100 and <1/10) Rare Hyperhidrosis ≥1/10,000 and <1/1,000
https://www.cslseqirus.co.nz/-/media/seqirus-new-zealand/documents/rabipur-datasheet-date-of-revision-20-feb-2025.pdf